• Traws Pharma advanced a proprietary broad-spectrum antiviral combination targeting ongoing Hantavirus and Ebola outbreaks, with potential utility against Lassa.
• Program centers on a dual mechanism to deplete host nucleotides, then drive viral RdRp to incorporate nucleoside mimics to halt replication.
• Both components have prior human safety data as single agents, supporting a lower-dose combination strategy to reduce toxicity risk.
• Non-clinical studies are underway in validated Hantavirus and Ebola animal models, using BSL-3 and BSL-4 laboratories.
• Chemical development and manufacturing scale-up is running in parallel to support potential emergency supply, stockpiling, and expedited regulatory engagement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-066623), on May 27, 2026, and is solely responsible for the information contained therein.